Enstilar® is now covered by the Alberta Drug Benefit List for Adults with Psoriasis Vulgaris
THORNHILL, ON, Dec. 3, 2018 /CNW/ – LEO Pharma Canada has announced that as of December 1st, 2018, Enstilar® has been added as a Regular Benefit through the Alberta Drug Benefit List.
Enstilar® (calcipotriol and betamethasone dipropionate) is a spray foam for once-daily topical treatment of psoriasis vulgaris in adults.
Psoriasis vulgaris is a chronic, immune-mediated, inflammatory skin disorder. It can occur as single lesions at predisposed sites (e.g., knees, elbows) or as a generalized disease across wider areas of the body, causing pain, disfigurement and disability.1,2 Although it is typically seen in adults, it can develop at any age with equal distribution between men and women.1
“This is a great vehicle and should increase patient adherence to the use of this medication. Public reimbursement will allow many more patients to benefit from this formulation,” said Dr. Kirk Barber, a board-certified dermatologist in Calgary, Alberta.
“I am very pleased to see that Enstilar® will be covered under the Alberta formulary coverage starting in December 2018 so more of our patients can have access to this effective medication,” said Dr. Parbeer Grewal, a board-certified dermatologist in Edmonton, Alberta.
“Enstilar® foam is first-line treatment for my patients with psoriasis, regardless of severity. Patient satisfaction is extremely high. I believe there is no better topical product for psoriasis,” said Dr. Vimal H. Prajapati, a board-certified dermatologist in Calgary, Alberta.
Psoriasis vulgaris affects approximately 1 million Canadians which equates to about 3% of the entire Canadian population.1,3
“This new format to apply a topical treatment should help with adherence for patients. We are looking forward to seeing Enstilar® available to all patients across Canada,” said Kathryn Andrews-Clay, Executive Director of the Canadian Association of Psoriasis Patients.
Enstilar® already received approval for the Régie de l’Assurance Maladie du Québec (RAMQ) on June 1st 2017, Saskatchewan Drug Plan on January 1st 2018, Non-Insured Health Benefits (NIHB) on October 15th 2018, New Brunswick Drug Plan on November 8th 2018, and Ontario Drug Benefit (ODB) on October 31st 2018.
Kristian Fick, President of LEO Pharma Canada, says, “Today marks a special day for those living with psoriasis in Alberta. At LEO Pharma our mission is to help people achieve healthy skin. We commend the Alberta Drug Benefit List for adding Enstilar® to the Formulary, and bringing us one step closer to achieving this mission. LEO is looking forward to working collaboratively with the remaining provinces and territories to ensure all patients with psoriasis have access to Enstilar®.”
Enstilar® is an aerosol spray foam containing calcipotriol monohydrate 50 mcg/g and betamethasone dipropionate 0.5 mg/g. It is indicated for the treatment of psoriasis vulgaris in adults for up to 4 weeks. On average, 120 g (2 cans x 60 g) of Enstilar® is used for the once-daily treatment of psoriasis for up to 4 weeks.4-7 Enstilar® has been available to Canadian patients since November 2016 and currently, it is estimated that 50,000 Canadian patients have been prescribed Enstilar®.
About LEO Pharma A/S
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 130 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company headquartered in Denmark has devoted decades of research and development to delivering products and solutions to people with skin conditions. In 2017 LEO Pharma employed around 5,200 people worldwide. Helping patients for more than 30 years in Canada, LEO Pharma Canada is a division of LEO Pharma A/S. To learn more about LEO Pharma’s products and commitment to dermatology care in Canada, visit: www.leo-pharma.ca.
|1.||Canadian Dermatology Association. Psoriasis. Available at: https://dermatology.ca/public-patients/skin/psoriasis/. Retrieved October 18, 2018.|
|2.||National Clinical Guideline Centre (UK). National Institute for Health and Clinical Excellence: Guidance. Psoriasis: Assessment and Management of Psoriasis. London: Royal College of Physicians (UK); 2012.|
|3.||Statistics Canada. Population. Available at: https://www150.statcan.gc.ca/n1/pub/12-581-x/2018000/pop-eng.htm. Retrieved October 23, 2018.|
|4.||Enstilar® Product Monograph. Leo Pharma Inc. September 8, 2016.|
|5.||Koo J, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris—A randomized phase II study. Journal of Dermatological Treatment. 2016;27(2):120-127.|
|6.||Leonardi C, et al. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris—a Randomized Phase III Study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468-1477.|
|7.||Lebwohl M, et al. Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. J Clin Aesthet Dermatol. 2016;9(2):34-41.|
SOURCE LEO Pharma Canada